Paris - Delayed Quote EUR

Valerio Therapeutics Société anonyme (ALVIO.PA)

0.0750

-0.0040

(-5.06%)

At close: 2:00:27 PM GMT+1

Valerio Therapeutics Acquires Emglev Therapeutics, a Single-Domain Antibody-Based Therapeutics Company

PARIS, September 30, 2024--Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), a clinical-stage biotechnology company leading the way in the development of innovative DNA Decoy therapeutics, today announced the acquisition of Emglev Therapeutics, a spinoff of Institut Curie, one of France's leading cancer centers.

Business Wire 2 months ago

ALVIO.PA
-5.06%
Half-Year Liquidity Contract Statement for Valerio Therapeutics

PARIS, August 05, 2024--Regulatory News: Under the liquidity contract entered into between VALERIO THERAPEUTICS (Paris:ALVIO) and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30, 2024:

Business Wire 4 months ago

ALVIO.PA
-5.06%
Valerio Therapeutics: Report on the Combined General Meeting of June 4, 2024

PARIS, June 05, 2024--Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today announced that the Combined (Ordinary and Extraordinary) General Meeting held today at 2 pm was able to validly deliberate with a quorum of 48.1%.

Business Wire 6 months ago

ALVIO.PA
-5.06%
Valerio Therapeutics Provides Clinical Development Update on Its Phase 1/2 VIO-01 Clinical Trial

PARIS, May 22, 2024--Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today announced the completion of dosing for the first cohort of subjects in its Phase 1/2 trial of lead candidate, VIO-01, a pan-DDR decoy for the treatment of solid tumors.

Business Wire 6 months ago

ALVIO.PA
-5.06%
Valerio Therapeutics Reports Full Year 2023 Financial Results and Provides Clinical Development Updates

PARIS, April 30, 2024--Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), hereafter "Valerio Therapeutics" or the "Company"), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today reported its consolidated results for the fiscal year ending December 31, 2023.

Business Wire 7 months ago

ALVIO.PA
-5.06%
Valerio Therapeutics Announces a Capital Reduction Motivated by Losses by Reducing the Nominal Value of the Company's Shares

PARIS, February 06, 2024--Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), hereafter "Valerio Therapeutics" or the "Company", a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), today announces a reduction of the par value of its shares.

Business Wire 10 months ago

ALVIO.PA
-5.06%

Performance Overview

Return	ALVIO.PA	CAC 40
YTD	-54.55%	-3.45%
1-Year	-54.95%	-3.78%
3-Year	-72.22%	+2.48%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Valerio Therapeutics Société anonyme (ALVIO.PA)

Valerio Therapeutics Acquires Emglev Therapeutics, a Single-Domain Antibody-Based Therapeutics Company

Half-Year Liquidity Contract Statement for Valerio Therapeutics

Valerio Therapeutics: Report on the Combined General Meeting of June 4, 2024

Valerio Therapeutics Provides Clinical Development Update on Its Phase 1/2 VIO-01 Clinical Trial

Valerio Therapeutics Reports Full Year 2023 Financial Results and Provides Clinical Development Updates

Valerio Therapeutics Announces a Capital Reduction Motivated by Losses by Reducing the Nominal Value of the Company's Shares

Performance Overview